CervoMed Shares Are Trading Higher After the Company Announced Its Orval Investigational Drug Neflamapimod Was Granted Orphan Drug Designation Status by the FDA for the Treatment of Frontotemporal Dementia.
CervoMed Shares Are Trading Higher After the Company Announced Its Orval Investigational Drug Neflamapimod Was Granted Orphan Drug Designation Status by the FDA for the Treatment of Frontotemporal Dementia.
CervoMed股票上漲，因爲公司宣佈其Orval探索性藥物Neflamapimod獲得FDA對顳顳葉癡呆症治療的孤兒藥物認可地位。
CervoMed Shares Are Trading Higher After the Company Announced Its Orval Investigational Drug Neflamapimod Was Granted Orphan Drug Designation Status by the FDA for the Treatment of Frontotemporal Dementia.
CervoMed的股票在公司宣佈其Orval實驗藥物Neflamapimod獲得FDA對前額顳葉癡呆治療的孤兒藥資格後上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間